Status:
UNKNOWN
Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation
Lead Sponsor:
Hebei Senlang Biotechnology Inc., Ltd.
Conditions:
AML
Eligibility:
All Genders
2-65 years
Phase:
NA
Brief Summary
This is an open single-arm clinical study aimed at evaluating the efficacy and safety of universal γδT cell injection in the treatment of patients with relapsed AML after transplantation
Detailed Description
Main purpose: To evaluate the safety and effectiveness of universal CAR-γδT cell injection in the treatment of patients with relapsed AML after transplantation Secondary purpose: to investigate the i...
Eligibility Criteria
Inclusion
- Patients with clinically diagnosed recurrence of AML after receiving transplant therapy;
- Flow cytometry (FCM) or immunohistochemical detection of tumor cells confirmed CD123 positive;
- Age ≥2 years old and \<65 years old;
- Survival is expected to be greater than 3 months from the date of signing of the informed consent;
- KPS 80 points or more;
- The functions of vital organs shall meet the following conditions:
- 1\) EF\>50%, and no obvious ECG abnormality; 2) SpO2 90% or more; 3) Cr 2.5 ULN or less; 4) ALT And AST≤5ULN, TBil≤3ULN; 7. Subjects who plan to become pregnant must agree before study enrollment and after study duration of 6 months Use contraception; Inform the investigator immediately if the subject is pregnant or suspected to be pregnant; 8. Subject or guardian understands and signs the informed consent;
Exclusion
- 1\. Other diseases that have not been effectively controlled, including but not limited to persistent or poorly controlled infections and diseases Congestive heart failure, unstable angina pectoris, arrhythmias, poorly controlled lung disease Or mental illness; 2. Other active malignant tumors; 3. Complicated with severe infection that cannot be effectively controlled; 4. Active hepatitis B (HBVDNA) or HCV RNA \[HCVRNA\] test was positive); 5. Human immunodeficiency virus (HIV) infection or syphilis infection; 6. Have a history of severe allergy to biological products (including antibiotics); 7. Acute graft-versus-host reaction (GVHD) was still present one month after discontinuation of immunosuppressant therapy Allogeneic hematopoietic stem cell transplantation patients; 8. Female subjects are in pregnancy and lactation; 9. Active autoimmune diseases requiring systemic immunosuppression; 10. Conditions that the investigator believes may increase the risk of the subject or interfere with the results of the test;
Key Trial Info
Start Date :
December 16 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 16 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04796441
Start Date
December 16 2020
End Date
February 16 2022
Last Update
March 12 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hebei yanda Ludaopei Hospital
Yanda, Hebei, China